Primary hypersomnias of central origin

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 1, 2013, Pages 67-85

  Malhotra, Samit ^b   Kushida, Clete A ^a  

^a STANFORD UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARMODAFINIL; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; HLA DQB1 ANTIGEN; IMIPRAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; PROTRIPTYLINE; VENLAFAXINE;

ANOREXIA; BEDTIME DOSAGE; BEHAVIOR THERAPY; CATAPLEXY; CLINICAL FEATURE; CONSTIPATION; DAYTIME SOMNOLENCE; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ENURESIS; EPWORTH SLEEPINESS SCALE; EVENING DOSAGE; EXCESSIVE DAYTIME SLEEPINESS; HALLUCINATION; HEART PALPITATION; HUMAN; HYPERSOMNIA; HYPERTENSION; IDIOPATHIC DISEASE; INSOMNIA; MENSTRUATION; MORNING DOSAGE; MULTIPLE SLEEP LATENCY TEST; MUSCLE ATONIA; NARCOLEPSY; NAUSEA; NEUROPATHOLOGY; NONHUMAN; PALLIATIVE THERAPY; PARASOMNIA; PATHOPHYSIOLOGY; PERIODIC LIMB MOVEMENT DISORDER; POLYSOMNOGRAPHY; PREVALENCE; PRIMARY HYPERSOMNIA; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHOSIS; REM SLEEP; REVIEW; SIDE EFFECT; SLEEP DISORDERED BREATHING; SLEEP WAKING CYCLE; SOMNOLENCE; TACHYCARDIA; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

CHILD; CREATINE; DISORDERS OF EXCESSIVE SOMNOLENCE; HLA-DQ BETA-CHAINS; HUMANS; MALE; NARCOLEPSY; POLYSOMNOGRAPHY;

EID: 84873630513     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000427212.05930.c4     Document Type: Review

References (43)

1. National Sleep Foundation. How much sleep do we really need? www.sleepfoundation. org/article/how-sleep-works/how-much-sleep-do-we-really- need. Accessed December 5, 2012.
2. American Academy of Sleep Medicine. International classification of sleep disorders, second edition: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine, 2005.
3. Schenck CH, Bassetti CL, Arnulf I, Mignot E. English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gélineau in the late 19th century, with commentary. J Clin Sleep Med 2007;3(3):301-311.
4. Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984;24(5):316-319. (Pubitemid 15199473)
5. Mignot E, Lin X, Arrigoni J, et al. DQB1&z.ast;0602 and DQA1&z.ast;0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994;17(8 suppl): S60-S67.
6. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95(1):322-327. (Pubitemid 28103952)
7. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355(9197):39-40. (Pubitemid 30072183)
8. Ohayon MM, Priest RG, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002;58(12):1826-1833. (Pubitemid 34663586)
9. Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003;114(11): 2000-2017. (Pubitemid 37298050)
10. Bassetti CL, Billiard M, Mignot E, eds. Lung biology in health and disease: narcolepsy and hypersomnia. Volume 220. New York, NY: Informa Healthcare, 2007.
11. Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004;13(4):395-406. (Pubitemid 39627363)
12. Mignot E, Hayduk R, Black J, et al. HLA DQB1&z.ast;0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20(11): 1012-1020. (Pubitemid 28042450)
13. Nishino S. The hypothalamic peptidergic system, hypocretin/orexin and vigilance control. Neuropeptides 2007;41(3):117-133. (Pubitemid 46695853)
14. Guilleminault C, Gelb M. Clinical aspects and features of cataplexy. AdvNeurol 1995;67: 65-77.
15. Overeem S, Reijntjes R, Huyser W, et al. Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. J Sleep Res 2004;13(3):257-264. (Pubitemid 39331186)
16. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14(6):540-545.
17. Richardson GS, Carskadon MA, Flagg W, et al. Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. Electroencephalogr Clin Neurophysiol 1978;45(5):621-627. (Pubitemid 9031575)
18. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005;28(1):113-121. (Pubitemid 40543126)
19. Nishino S, Deguzman C, Yamadera W, et al. Neurochemistry and biomarkers of narcolepsy and other primary and secondary hypersomnias. Sleep Med Clin 2012;7(2):233-248.
20. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68(5):2032-2037. (Pubitemid 27176139)
21. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000;1(2):109-116.
22. Nishino S, Okuro M. Armodafinil for excessive daytime sleepiness. Drugs Today (Barc) 2008;44(6):395-414.
23. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6(5): 415-421.
24. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30(12): 1705-1711. (Pubitemid 350234749)
25. Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000;4(5):471-503.
26. Fujiki N, Yoshida Y, Ripley B, et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003;26(8):953-959. (Pubitemid 39619754)
27. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-266.
28. Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with "sleep drunkenness." Arch Gen Psychiatry 1972;26(5):456-462.
29. Aldrich MS. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996;46(2):393-401. (Pubitemid 26081320)
30. Heier MS, Evsiukova T, Vilming S, et al. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007;30(8): 969-973. (Pubitemid 47221896)
31. Bruck D, Parkes JD. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. J Neurol Neurosurg Psychiatry 1996;60(5):576-578. (Pubitemid 26147902)
32. Montplaisir J, Fantini L. Idiopathic hypersomnia: a diagnostic dilemma. A commentary of "Idiopathic hypersomnia" (M. Billiard and Y. Dauvilliers). Sleep Med Rev 2001;5(5):361-362. (Pubitemid 33089567)
33. Critchley M, Hoffman H. The syndrome of periodic somnolence and morbid hunger (Kleine-Levin syndrome). Br Med J 1942;1(4230):137-139.
34. Arnulf I, Zeitzer JM, File J, et al. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain 2005;128(pt 12): 2763-2776. (Pubitemid 41746631)
35. Arnulf I, Lin L, Gadoth N, et al. Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol 2008;63(4):482-493. (Pubitemid 351614714)
36. Huang YS, Lin YH, Guilleminault C. Polysomnography in Kleine-Levin syndrome. Neurology 2008;70(10):795-801.
37. Huang YS, Guilleminault C, Kao PF, Liu FY. SPECT findings in the Kleine-Levin syndrome. Sleep 2005;28(8):955-960. (Pubitemid 41170930)
38. Podestá C, Ferreras M, Mozzi M, et al. Kleine-Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements. Sleep Med 2006;7(8):649-651. (Pubitemid 44815276)
39. Carpenter S, Yassa R, Ochs R. A pathologic basis for Kleine-Levin syndrome. Arch Neurol 1982;39(1):25-28. (Pubitemid 12194170)
40. Muratori F, Bertini N, Masi G. Efficacy of lithium treatment in Kleine-Levin syndrome. Eur Psychiatry 2002;17(4):232-233. (Pubitemid 34987828)
41. Surges R, Walker MC. A case of late-onset Kleine-Levin syndrome responding to lamotrigine. Sleep Med 2009;10(3):394.
42. Crumley FE. Valproic acid for Kleine-Levin syndrome. J Am Acad Child Adolesc Psychiatry 1997;36(7):868-869.
43. Billiard M, Jaussent I, Dauvilliers Y, Besset A. Recurrent hypersomnia: A review of 339 cases. Sleep Med Rev 2011;15(4):247-257.